𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis

✍ Scribed by Dr. Ashok K. Batta; Gerald Salen; Renu Arora; Sarah Shefer; G. Stephen Tint; John Abroon; David Eskreis; Seymour Katz


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
571 KB
Volume
10
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


We have compared the effect of ursodeoxycholic acid with placebo on the clinical state, blood liver chemistries and serum and urinary bile acids in four patients with primary biliary cirrhosis. All parameters were evaluated monthly, and bile acid composition was measured by capillary gas-liquid chromatography. At the time of admission, all patients showed intense pruritus, and their serum alkaline phosphatase, AST and ALT levels were elevated 4.3,2.7 and 2.3 times over control values. Serum bile acids were elevated almost 38-fold with 2.5 times more cholic acid than chenodeoxycholic acid. Urinary bile acid output was elevated 2 8 times the control values, and 36% were 1P-hydroxycholic acid, lp-hydroxydeoxycholic acid and hyocholic acid (3a,6a,7a- trihydroxy-5/3-cholanoic acid). Three months of placebo administration did not significantly affect the clinical or biochemical presentations, and the serum and urinary bile acid composition did not change. In contrast, ursodeoxycholic acid feeding (12 to 15 mg per kg per day) for 6 months abolished pruritus in two and lessened itching in two subjects and reduced serum alkaline phosphatase, AST and ALT levels by 21, 35 and 47%, respectively. The mean values for the total serum bile acid concentrations in these patients declined 26% from the pretreatment value, but the proportion of ursodeoxycholic acid increased from 3 to 40% of the total bile acids; thus, total fasting serum endogenous bile acid levels decreased almost 50%. Similar changes were noted in the urinary bile acids, in which ursodeoxycholic acid became the major bile acid, and approximately 18% were hydroxylated at C-1, C-6 and C-21. These results demonstrate that, compared with placebo, ursodeoxycholic acid significantly lowers serum and urinary bile acids in primary biliary cirrhosis and produces considerable clinical and biochemical improvement.


πŸ“œ SIMILAR VOLUMES


Biliary bile acids in primary biliary ci
✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Santiago Munoz; Guada πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 1 views

Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed

Ursodeoxycholic acid therapy in primary
✍ David E. J. Jones; Oliver F. W. James; Margaret F. Bassendine πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 703 KB

BackgroundlAims: A double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) was conducted in 180 patients with primary biliary cirrhosis (PBC) to define the efficacy and safety of UDCA Efficacy was assessed by time to treatment failure defined as death; liver transplantation; histologic

No relevant effect of ursodeoxycholic ac
✍ Karin Dilger; Annette Denk; Malte H. J. Heeg; Ulrich Beuers πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 183 KB

Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous

Cholesterol-lowering effect of ursodeoxy
✍ RenΓ©e E. Poupon; Khadija Ouguerram; Yves ChrΓ©tien; Claudine Verneau; Eveline Esc πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 591 KB

We have previously shown in a 2-yr controlled trial that hypercholesterolemia, frequent in primary biliary cirrhosis, is lowered by ursodeoxycholic acid (13 to 15 mg daily). To further investigate this effect, we analyzed the influence of long-term ursodeoxycholic acid administration on serum lipids